GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (STU:LX31) » Definitions » Shiller PE Ratio

Lexicon Pharmaceuticals (STU:LX31) Shiller PE Ratio : (As of Jun. 09, 2024)


View and export this data going back to . Start your Free Trial

What is Lexicon Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lexicon Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Lexicon Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals Shiller PE Ratio Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lexicon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lexicon Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Lexicon Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexicon Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's Shiller PE Ratio falls into.



Lexicon Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lexicon Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Lexicon Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.184/131.7762*131.7762
=-0.184

Current CPI (Mar. 2024) = 131.7762.

Lexicon Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.258 100.560 -0.338
201409 -0.427 100.428 -0.560
201412 -0.028 99.070 -0.037
201503 -0.249 99.621 -0.329
201506 -0.241 100.684 -0.315
201509 -0.303 100.392 -0.398
201512 0.698 99.792 0.922
201603 -0.305 100.470 -0.400
201606 -0.329 101.688 -0.426
201609 -0.312 101.861 -0.404
201612 -0.294 101.863 -0.380
201703 -0.309 102.862 -0.396
201706 -0.294 103.349 -0.375
201709 -0.243 104.136 -0.307
201712 -0.228 104.011 -0.289
201803 -0.324 105.290 -0.406
201806 -0.282 106.317 -0.350
201809 -0.223 106.507 -0.276
201812 -0.141 105.998 -0.175
201903 -0.186 107.251 -0.229
201906 -0.195 108.070 -0.238
201909 1.771 108.329 2.154
201912 -0.432 108.420 -0.525
202003 -0.570 108.902 -0.690
202006 -0.577 108.767 -0.699
202009 0.603 109.815 0.724
202012 -0.033 109.897 -0.040
202103 -0.126 111.754 -0.149
202106 -0.108 114.631 -0.124
202109 -0.136 115.734 -0.155
202112 -0.150 117.630 -0.168
202203 -0.145 121.301 -0.158
202206 -0.151 125.017 -0.159
202209 -0.131 125.227 -0.138
202212 -0.151 125.222 -0.159
202303 -0.159 127.348 -0.165
202306 -0.203 128.729 -0.208
202309 -0.197 129.860 -0.200
202312 -0.183 129.419 -0.186
202403 -0.184 131.776 -0.184

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lexicon Pharmaceuticals  (STU:LX31) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Lexicon Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexicon Pharmaceuticals (STU:LX31) Business Description

Traded in Other Exchanges
Address
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Lexicon Pharmaceuticals (STU:LX31) Headlines

No Headlines